2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

1985 Treatment-free remission after TKI Discontinuation in Pediatric and adolescent CML-CP: A multicenter retrospective Study in China

Yingling Zu, Na Xu2, Yu Zhu, MD3, Bingcheng LIU, MD4, Jianyu Weng, MD, PhD5, Huanling Zhu6, Zhenfang Liu7, Guohui Li, MD8, Yunfan Yang, MD9, Shuxia Guo10, HUIFANG ZHAO11, Li Weiming, MD12, Qian Jiang Jr, MD13, Yanli Zhang, MD14
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 Nanfang Hospital, Southern Medical University, Guangzhou, China
3 The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
4 Institute of Haematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
6 West China Hospital, Chengdu, China
7 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
8 Xi’an international medical center hospital, Xi’an, China
9 West China Hospital, Chengdu, China
10 Zhengzhou People's Hospital, Zhengzhou, China
11 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
12 Union hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China
13 Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China
14 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Background: Tyrosine kinase inhibitor (TKI) therapy has markedly improved long-term survival of pediatric and adolescents with chronic myeloid leukemia in chronic phase (CML-CP). For patients with sustained deep molecular responses (DMR), treatment-free remission (TFR) has become an optimal therapeutic goal to eliminate lifelong TKI exposure and subsequent toxicities. Current TFR guidelines and clinical evidence are predominantly established on adult populations and limited single-center pediatric studies. Large multicenter real-world data regarding TFR efficacy, safety profiles, relapse kinetics, and independent prognostic factors in Chinese pediatric and adolescent CML patients remain underrepresented. This national multicenter study aimed to evaluate real-world TFR outcomes following standardized TKI discontinuation in pediatric and adolescent CML-CP patients, and to identify robust predictive factors for durable TFR, thereby optimizing age-tailored TFR strategies for this unique population. Methods: A retrospective multicenter cohort study was conducted enrolling pediatric and adolescent patients diagnosed with CML-CP before 19 years of age who underwent TKI discontinuation at 11 centers from October 2017 to December 2025. All participating centers adopted unified discontinuation criteria and molecular monitoring protocols compliant with ELN CML guidelines, requiring sustained MR4.0 or deeper molecular response for a minimum of 24 consecutive months on first- or second-generation TKI therapy. The primary endpoint was the 12-month TFR rate after TKI cessation. Secondary endpoints included the 24-month TFR rate, patterns of molecular relapse (defined as BCR-ABL >0.1%), and post-discontinuation safety events. Kaplan–Meier analysis was performed to estimate TFR rates, and multivariate Cox proportional hazards regression models were utilized to identify independent prognostic factors for TFR failure. Results: In total, 124 pediatric and adolescent CML-CP patients were included in the final analysis. The median age at diagnosis was 15 years (range, 1-18), and the median age at TKI discontinuation was 22 years (range, 9-27), with 58% male patients. Initial TKI regimens consisted of imatinib (88.7%, n=110), nilotinib (7.3%, n=9), dasatinib (3.2%, n=4), and flumatinib (0.8%, n=1). The median post-discontinuation follow-up was 34.5 months (range, 6-121), with a median total TKI treatment duration of 96 months (range, 36-226). The median time to first MR4.0 achievement was 18 months (range, 2-178). Prior to discontinuation, the median sustained duration of MR4.0 and MR4.5 was 71.5 months (range, 24-178) and 64 months (range, 24-178), respectively. The 12-month and 24-month TFR rates were 74.0% (95% CI: 69.6%-78.4%) and 65.3% (95% CI: 60.8%-70.1%), respectively. TKI withdrawal syndrome occurred in 10.5% (13/124) of patients. Molecular relapse developed in 43 patients at a median of 5 months post-discontinuation (range, 1-46), with 81.4% of relapses occurring within the first 12 months. Following TKI re-initiation, 93.0% and 79.1% of relapsed patients re-attained stable MMR and MR4.0, without disease progression or severe adverse events. Multivariate analysis confirmed diagnosis age <8 years and pre-discontinuation MR4.0 duration ≥88 months as independent protective factors for durable TFR. All patients remained alive at last follow-up, with 74.2% achieving MR4.5, 9.7% achieving MR4.0, 8.1% achieving MMR, and 8.1% achieving CCyR. Conclusion: This large-scale national multicenter real-world study demonstrates that standardized TKI discontinuation is safe and feasible for pediatric and adolescent CML-CP patients, yielding durable. Younger age at diagnosis and prolonged pre-discontinuation DMR duration serve as independent, robust protective factors for sustained TFR in this cohort. These multicenter real-world findings provide reliable clinical evidence to support individualized TKI discontinuation decision-making for pediatric and adolescent CML patients in routine practice.
Yingling Zu: No relevant conflicts of interest to declare.